RXRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Recursion Pharmaceuticals (RXRX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown significant revenue growth and improved financial management, the stock's technical indicators are mixed, and the lack of strong trading signals or significant positive catalysts suggests a cautious approach. Holding off for further developments or a more favorable entry point is recommended.
The MACD is positive and expanding, indicating a slight bullish momentum. However, the RSI is neutral at 57.975, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting an overall downward trend. The stock is currently trading near its pivot level of 3.543, with resistance at 3.963 and support at 3.122.
Q4 2025 revenue increased by 681.1% YoY due to a milestone payment from Roche.
Improved financial management with reduced operating expenses by 35% YoY.
JPMorgan's upgrade to Overweight, citing strong efficacy of REC-4881 and broader addressable market potential.
BofA lowered the price target from $7 to $6, citing delayed REC-617 launch and revised estimates.
Pre-market price is down by 1.86%, reflecting weak sentiment.
Gross margin dropped significantly YoY, and net income remains negative.
In Q4 2025, revenue surged to $35.54 million (+681.74% YoY), driven by a milestone payment. However, net income dropped to -$108.12 million (-39.56% YoY), and EPS fell to -$0.21 (-60.38% YoY). Gross margin also declined significantly to 59.83 (-132.98% YoY).
Mixed sentiment from analysts. JPMorgan upgraded the stock to Overweight with a price target of $11, citing strong prospects for REC-4881 and REC-617. However, BofA lowered its price target to $6 and maintained a Neutral rating, citing delays in REC-617 and revised estimates.
